Clinical practice. Screening for prostate cancer.

Current recommendations for prostate-specific antigen testing are reviewed, as well as the initial results of two randomized trials. The potential risks of screening, including morbidity from overdiagnosis and overtreatment, are described.

[1]  Peter H Gann,et al.  Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.

[2]  H. Klocker,et al.  Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality , 2008, BJU international.

[3]  B. Rimer,et al.  Informed decision making: What is its role in cancer screening? , 2004, Cancer.

[4]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Levinson,et al.  Informed decision making in outpatient practice: time to get back to basics. , 1999, JAMA.

[6]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[7]  E. Metter,et al.  What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Gohagan,et al.  Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial , 2008, BJU international.

[9]  C. Lawton.  Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer , 2012 .

[10]  A. S. Kibel.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009 .

[11]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[12]  D. Bates,et al.  The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes , 2006, Journal of General Internal Medicine.

[13]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[14]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[15]  Michael J Barry,et al.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut , 2002, BMJ : British Medical Journal.

[16]  Christopher Coley,et al.  CLINICAL GUIDELINE: PART 1: Early Detection of Prostate Cancer: Part I , 1997, Annals of Internal Medicine.

[17]  R. Piana.  Mortality results from the Göteborg prostate-cancer screening trial , 2010 .

[18]  P. Lange,et al.  Newer potential biomarkers in prostate cancer. , 2007, Reviews in urology.

[19]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[20]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[21]  T. Wilt,et al.  The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. , 2009, Contemporary clinical trials.

[22]  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.

[23]  Brian J Zikmund-Fisher,et al.  Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). , 2009, Archives of internal medicine.

[24]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[25]  M. Mushinski,et al.  Probabilities of eventually developing or dying of cancer—united states, 1985 , 1985, CA: a cancer journal for clinicians.

[26]  G. Murphy,et al.  American Cancer Society guideline for the early detection of prostate cancer: Update 1997 , 1997, CA: a cancer journal for clinicians.

[27]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[28]  J. Holmes,et al.  Are Physicians Discussing Prostate Cancer Screening with Their Patients and Why or Why Not? A Pilot Study , 2007, Journal of General Internal Medicine.

[29]  T H Beaty,et al.  Family history and the risk of prostate cancer , 1990, The Prostate.

[30]  H. Carter,et al.  Update on PSA testing. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  Z. Hall.  Cancer , 1906, The Hospital.

[32]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[33]  Robert J Volk,et al.  Trials of decision aids for prostate cancer screening: a systematic review. , 2007, American journal of preventive medicine.

[34]  W. Catalona,et al.  Interexaminer variability of digital rectal examination in detecting prostate cancer. , 1995, Urology.

[35]  Michael J Barry,et al.  Health Decision Aids To Facilitate Shared Decision Making in Office Practice , 2002, Annals of Internal Medicine.

[36]  Dante diTommaso,et al.  Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.

[37]  Adam S. Kibel,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .

[38]  T. Wilt,et al.  Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.

[39]  Curtis Mettlin,et al.  Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers , 1993, CA: a cancer journal for clinicians.

[40]  Lisa M. Schwartz,et al.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? , 2003, JAMA.

[41]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[42]  J. Concato,et al.  The effectiveness of screening for prostate cancer: a nested case-control study. , 2006, Archives of internal medicine.

[43]  A. Potosky,et al.  Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA , 2005, BMC Cancer.

[44]  Harry J de Koning,et al.  Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). , 2009, European urology.

[45]  L. Klotz,et al.  Active surveillance for prostate cancer: patient selection and management. , 2010, Current oncology.

[46]  Hans Garmo,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[48]  G. Chodak,et al.  Assessment of screening for prostate cancer using the digital rectal examination. , 1989, The Journal of urology.

[49]  F. Hamdy,et al.  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. , 2008, The Lancet. Oncology.